Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHSG-KF vs split-thickness skin grafts in pediatric deep dermal and full-thickness burns
2024-512189-33-00Phase 2Authorised
- Sponsor
- CUTISS
- Start
- Oct 2024
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of denovoSkin in deep second-degree burn and burn injury (2 arms), sponsored by CUTISS. Primary endpoint: Primary efficacy endpoint: graft take ratio at 28 days. Planned start Oct 2024; status: authorised.
02
Drugs
denovoSkin
03
Conditions
deep second-degree burnburn injury
Beyond the preview
Go deeper on 2024-512189-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512189-33-00.